Positive Data on RECCE 327 Against Neisseria gonorrhoeae
Filed with ASX · · 4 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Further Positive Data on RECCE 327 Against MRSA Superbug
- Positive Data on RECCE 327 Against Influenza A
- Recce Signs Phase I Human Clinical Trial Agreement
- First-in-Human Clinical Trial Progress Update
- Half Yearly Report and Accounts
Later from Recce Pharmaceuticals
- Response to ASX Price and Volume Query
- RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
- US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
- Positive Oral Data on New RECCE 435 Against H. pylori
- Recce Pharmaceuticals Appoints James Graham as CEO
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals